

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced and/or metastatic ovarian cancer

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Roche Products (bevacizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • CANCERactive • Cancer Black Care • Cancer Equality • Cancer 52 • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Gynae C • Helen Rollason Heal Cancer Charity • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Ovacome • Ovarian Cancer Action • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Target Ovarian Cancer • Tenovus • Well Being of Women • Women's Health Concern 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Possible Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Abraxis Bioscience (paclitaxel) • Actavis UK (paclitaxel) • Bristol Myers Squibb (carboplatin, paclitaxel) • <u>Goldshield (cisplatin)</u> • Hospira (carboplatin, cisplatin, paclitaxel) • Medac GmbH (paclitaxel) • Pfizer (cisplatin) • Teva UK (carboplatin, cisplatin,

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced and/or metastatic ovarian cancer

Issue date: August 2010

Page

Consultees	Commentators (no right to submit or appeal)
<p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Association of Surgical Oncology • British Geriatrics Society • British Gynaecological Cancer Society • British Oncological Association (BOA) • British Psychosocial Oncology Society • Cancer Networks Pharmacists Forum • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians & Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Aneurin Bevan Health Board • Department of Health • NHS Waltham Forest • Welsh Assembly Government 	<p>paclitaxel)</p> <ul style="list-style-type: none"> • Wockhardt (carboplatin, cisplatin, paclitaxel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Eve appeal • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.